Sana Biotechnology, Inc. – NASDAQ:SANA
Sana Biotechnology stock price today
$3.42
+1.80
+112.42%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Sana Biotechnology stock price monthly change
-72.94%
month
Sana Biotechnology stock price quarterly change
-72.94%
quarter
Sana Biotechnology stock price yearly change
-62.30%
year
Sana Biotechnology key metrics
Market Cap | 360.57M |
Enterprise value | 618.94M |
P/E | -2.5 |
EV/Sales | N/A |
EV/EBITDA | -1.77 |
Price/Sales | N/A |
Price/Book | 1.37 |
PEG ratio | -0.09 |
EPS | -1.52 |
Revenue | N/A |
EBITDA | -284.89M |
Income | -308.60M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSana Biotechnology stock price history
Sana Biotechnology stock forecast
Sana Biotechnology financial statements
Average Price Target
$8
Potential upside: 133.91%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -113.99M | |
|---|---|---|---|
| Sep 2023 | 0 | 984K | |
| Dec 2023 | 0 | -88.11M | |
| Mar 2024 | 0 | -107.47M |
| Jun 2023 | 707147000 | 352.11M | 49.79% |
|---|---|---|---|
| Sep 2023 | 631440000 | 265.58M | 42.06% |
| Dec 2023 | 565299000 | 277.79M | 49.14% |
| Mar 2024 | 681377000 | 306.23M | 44.94% |
| Jun 2023 | -58.80M | 42.62M | 29.50M |
|---|---|---|---|
| Sep 2023 | -63.55M | 51.34M | 187K |
| Dec 2023 | -51.95M | 15.31M | 1.71M |
| Mar 2024 | -65.63M | -77.22M | 186.39M |
Sana Biotechnology alternative data
| Sep 2023 | 424 |
|---|---|
| Oct 2023 | 424 |
| Nov 2023 | 424 |
| Dec 2023 | 418 |
| Jan 2024 | 418 |
| Feb 2024 | 418 |
| Mar 2024 | 328 |
| Apr 2024 | 328 |
| May 2024 | 328 |
| Jun 2024 | 328 |
| Jul 2024 | 328 |
Sana Biotechnology other data
30.62%
-37.17%
of SANA is owned by hedge funds
67
-49
57.66M
-70.65M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 75000 |
| Feb 2024 | 5999999 | 0 |
| Mar 2024 | 0 | 25000 |
| Sep 2024 | 0 | 300000 |
| Insider | Compensation |
|---|---|
Dr. Richard C. Mulligan Ph.D. (1955) Executive Vice Chairman & Head of SanaX | $954,450 |
Dr. Steven D. Harr (1970) Pres, Chief Executive Officer & Director | $829,250 |
Mr. Christian Hordo M.B.A. (1983) Senior Vice President & Chief Bus. Officer | $485,030 |
Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Omega Therapeutics: The Next Weight Loss Drug Runner
Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
Sana Biotechnology: Hypoimmune Platform Might Stealth Cells
Sana Biotechnology Is Technically Overbought So Buy It Later
Sana Biotechnology: Time And Cash Burn Are The Enemies
Sana Biotechnology A Buy On Low Price And First IND
Week 28 MDA Breakout Stocks - July 2022: Short-Term Picks To Give You An Edge
-
What's the price of Sana Biotechnology stock today?
One share of Sana Biotechnology stock can currently be purchased for approximately $3.42.
-
When is Sana Biotechnology's next earnings date?
Unfortunately, Sana Biotechnology's (SANA) next earnings date is currently unknown.
-
Does Sana Biotechnology pay dividends?
No, Sana Biotechnology does not pay dividends.
-
How much money does Sana Biotechnology make?
Sana Biotechnology has a market capitalization of 360.57M.
-
What is Sana Biotechnology's stock symbol?
Sana Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "SANA".
-
What is Sana Biotechnology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sana Biotechnology?
Shares of Sana Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sana Biotechnology's key executives?
Sana Biotechnology's management team includes the following people:
- Dr. Richard C. Mulligan Ph.D. Executive Vice Chairman & Head of SanaX(age: 70, pay: $954,450)
- Dr. Steven D. Harr Pres, Chief Executive Officer & Director(age: 55, pay: $829,250)
- Mr. Christian Hordo M.B.A. Senior Vice President & Chief Bus. Officer(age: 42, pay: $485,030)
-
How many employees does Sana Biotechnology have?
As Jul 2024, Sana Biotechnology employs 328 workers.
-
When Sana Biotechnology went public?
Sana Biotechnology, Inc. is publicly traded company for more then 4 years since IPO on 4 Feb 2021.
-
What is Sana Biotechnology's official website?
The official website for Sana Biotechnology is sana.com.
-
Where are Sana Biotechnology's headquarters?
Sana Biotechnology is headquartered at 188 East Blaine Street, Seattle, WA.
-
How can i contact Sana Biotechnology?
Sana Biotechnology's mailing address is 188 East Blaine Street, Seattle, WA and company can be reached via phone at +20 67 017914.
-
What is Sana Biotechnology stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Sana Biotechnology in the last 12 months, the avarage price target is $8. The average price target represents a 133.91% change from the last price of $3.42.
Sana Biotechnology company profile:
Sana Biotechnology, Inc.
sana.comExchange:
NASDAQ
Full time employees:
328
Industry:
Biotechnology
Sector:
Healthcare
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
188 East Blaine Street
Seattle, WA 98102
Seattle, WA 98102
CIK: 0001770121
ISIN: US7995661045
CUSIP: 799566104
